p53 Family in Cancer: How Close Are We to the Clinic? (2nd Edition)
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".
Deadline for manuscript submissions: 20 June 2026 | Viewed by 385
Special Issue Editors
Interests: cancer pharmacology; targeted therapy; drug discovery; p53 family proteins
Special Issues, Collections and Topics in MDPI journals
2. Departamento de Genética Humana, Instituto Nacional de Saúde Doutor Ricardo Jorge, Avenida Padre Cruz, 1649-016 Lisboa, Portugal
3. BioISI—BioSystems & Integrative Sciences, Faculdade de Ciências, Universidade de Lisboa, Lisboa, Portugal
Interests: p53; p53 mRNA; p53 isoforms; mRNA translation; mRNA functions; cancer genetics
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
This Special Issue is a continuation of our previous one, entitled "p53 Family in Cancer: How Close Are We to the Clinic?”.
Many years of research have uncovered impressive knowledge about p53 family proteins and their critical roles in cancer. The p53 protein has been one of the most studied tumor suppressors in human cancer, owing to its multifaceted functions in cellular homoeostasis and tumorigenesis. The p53 relatives, p63 and p73, are entangled in the same regulatory network, actively contributing to the cellular outcome. The emerging picture is that of an interconnected pathway, in which all the p53 family proteins are involved in the response to oncogenic stress and physiological inputs. Dysregulations in the p53 family pathways are common events in human cancers and considerably affect the response to therapy. Notably, numerous studies relating to the (re)activation of the p53/p63/p73 function have shown encouraging therapeutic benefits. Nonetheless, much knowledge still needs to be acquired concerning the multiple contributions of this intriguing family of proteins in cancer development and anticancer therapies.
With this Special Issue, we are pleased to invite you to submit your work describing recent advances in this field, which may pave the way for more effective therapeutic strategies against cancer. In this issue, original research articles and reviews are welcome. The research areas may include (but are not limited to) basic and more (pre)clinical aspects of the function, biology, and pharmacology of the p53 family.
We look forward to receiving your contributions.
Dr. Lucília Saraiva
Dr. Marco M. Candeias
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- p53
- p63
- p73
- proteins
- protein-coding and non-coding genes
- genetics
- drug discovery
- cancer
- targeted anticancer therapy
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
